Abstract. Histone deacetylase (HDAC) inhibitors exert potent inhibitory effects on various types of human cancer. The pioneer drug suberoylanilide hydroxamic acid (SAHA) is currently used in the clinic for cancer treatment. However, the effect of SAHA on tumor lymphangiogenesis is unclear. We recently showed that SAHA suppresses the expression and production of pro-lymphagenic factor vascular endothelial growth factor-C (VEGF-C) in breast cancer cells. In the present study, the effect of SAHA on lymphatic endothelial cells (LECs) was examined. We generated a lymphatic-like endothelial cell line (named FP01) by overexpressing the master LEC transcription factor PROX1 in EA.hy926 endothelial cells. This cell line exhibited a gene expression pattern and phenotype similar to primarily cultured LECs. SAHA inhibited cell cycle progression and proliferation of FP01 cells. In addition, SAHA suppressed sprouting and tube formation in these cells. Moreover, SAHA attenuated the angiopoietin (Ang)/Tie signaling pathway which plays important roles in the regulation of LEC function. FP01 cells expressed Ang1, Ang2, Tie1 and Tie2, and SAHA dose-dependently reduced the expression of Tie2 in these cells. Tie2 promoter activity was attenuated by SAHA indicating a transcriptional repression. Importantly, Tie2 protein was significantly reduced by SAHA at the concentration in which no alteration of Tie2 mRNA was detected. We found that SAHA enhanced Tie2 protein degradation via the ubiquitin-proteasome pathway, and the expression of c-Cbl, the E3 ligase for Tie2 ubiquitination, rapidly increased after SAHA treatment. Knockdown of c-Cbl reversed SAHA-induced Tie2 protein degradation.
Introduction
Targeting of epigenetic alterations such as DNA methylation and histone modification is an important field for cancer research and for anticancer drug development (1, 2) . One class of promising epigenetic drugs is histone deacetylase (HDAC) inhibitors. These inhibitors suppress the enzymatic activity of HDAC and induce re-activation of tumor-suppressor genes or downregulation of oncogenes to attenuate tumor growth. Among HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) is a pioneer drug that has been developed and is now approved for the treatment of cutaneous T cell lymphoma (3, 4) . This drug is also undergoing clinical trials for the treatment of solid tumors. Several mechanisms are involved in the inhibition of tumor progression by SAHA. First, SAHA induces apoptosis in cancer cells by regulating pro-apoptotic or anti-apoptotic genes (5, 6) . Second, SAHA inhibits cell cycle progression by increasing the expression of anti-proliferative genes such as cyclin-dependent kinase inhibitors (CDKIs) p21 and p27 to reduce cell growth (7, 8) . Third, SAHA modulates the immune response to improve anticancer immune surveillance (9, 10) . Fourth, SAHA suppresses proliferation of endothelial cells or induces their apoptosis to decrease tumor angiogenesis in vivo (11) .
Recent studies demonstrate that induction of lymphangiogenesis is strongly associated with tumor metastasis and poor prognosis in cancer patients (12) (13) (14) . Proliferation, maturation and remodeling of lymphatic vessels are controlled by different signaling pathways. Accumulating evidence suggests that angiopoietin (Ang)/Tie signaling is an important regulator in angiogenesis and lymphangiogenesis. The Ang family includes four ligands (Ang1, Ang2 and Ang3/4) and two cognate receptors (Tie1 and Tie2). Results of previous studies suggest that Ang1 mainly acts as a Tie2 receptor agonist and Ang2 normally functions as an antagonist (15, 16) . However, the role of Ang1 and Ang2 is cell context-dependent and Ang2 may function as a partial agonist under some physiological Tie2 signaling of lymphatic endothelial cells by  the histone deacetylase inhibitor SAHA   HSUEH-TSEN CHENG  1 and WEN-CHUN HUNG conditions (17, 18) . Upon ligand stimulation, Tie2 forms a dimer or multimer and is autophosphorylated at tyrosine residues near its carboxyl terminus (19) . Activated Tie2 then transmits the signaling via several downstream molecules including downstream of tyrosine kinase-related protein (DOKR), endothelial nitric oxide synthase (eNOS), SH2 domain-containing phosphatase (SHP2), growth factor receptor-bound protein 2 (GRB2) and the p85 subunit of PI3K to elicit different biological processes (20, 21) . Mice lacking Ang2 exhibit major lymphatic vessel defects suggesting the importance of Ang2 in lymphatic function (22) . Interestingly, Ang1 has also been demonstrated to promote lymphatic vessel formation and can rescue the lymphatic defect of Ang2-mutant mice (23) . In addition, Ang1/Tie2 signaling enhances lymphatic integrity by modulating tight junction molecule expression during inflammation (24) . Although SAHA has been shown to inhibit tumor angiogenesis, its effect on tumor lymphangiogenesis and the Ang/Tie system is still unclear. In this study, we addressed this issue and tried to elucidate the underlying mechanism. Construction of Tie-2 promoter and luciferase assay. The genomic DNA was isolated from EA.hy926 cells by using the genomic DNA extraction kit (Qiagen, Hilden, Germany), and the -703/+232 region from transcription start site of Tie2 gene (NM_000459) was amplified by PCR using two specific primers: Tie2-703 forward, 5'-ATACTCGAGCTTGGGGCTA CATTGAGCAT-3' and reverse, 5'-ATTAAGCTTCACAGA GCCTTTGCATTTCA-3'. The amplified DNA fragment was subcloned into the luciferase reporter gene vector pGL3 (Promega, Madison, WI, USA) by XhoI and HindIII to yield the luciferase reporter construct pGL3-Tie2-(-703/+232). Using this construct as a template, two 5'-deletion constructs were generated by the following primers: Tie2-357 forward, 5'-AAA CTCGAGTACAGCAGCAGCAAAAGCAG-3' and Tie2-138 forward, 5'-ATACTCGAGGTTCCTTCTTGCCTCTAACTT GT-3'. FP01 cells were seeded into 6-well plates and transfected with 1 µg of serial Tie-2 promoter-luciferase plasmids. After 24 h, cells were incubated with various concentrations of SAHA for an additional 24 h. The luciferase activity was detected by a reporter assay system according to the manufacturer's instructions (Promega), and the results were normalized to the protein concentration in cell lysates.
Inhibition of proliferation, sprouting, tube formation and

Materials and methods
Generation of the
Reverse transcription-polymerase chain reaction (RT-PCR).
Cells were treated with different concentrations of SAHA for 24 h. Total RNA was isolated by using the RNeasy Mini kit (Qiagen), and mRNAs were reverse-transcribed to cDNA by M-MLV reverse transcriptase (Promega), using oligo-dT primers according to the manufacturer's instructions. The conditions of the PCR reaction included an initialization step for 5 min at 95˚C, 30 cycles of amplification (1 min at 95˚C for denaturation, 1 min at 60˚C for annealing and 1 min at 72˚C for elongation) and 7 min at 72˚C for final extension. The PCR primers were: Tie2 forward, 5'-AGTTCGAGGAGAGGC AATCA-3' and reverse, 5'-CCGAGGTGAAGAGGTTTCCT-3'; Tie1 forward, 5'-TTTAACCCTGGTGTGCATCC-3' and reverse, 5'-CCGCAGAAAATCTAGCAGGT-3'; Ang1 forward, 5'-TATGCCAGAACCCAAAAAGG-3' and reverse, 5'-GGGCACATTTGCACATACAG-3'; Ang2 forward, 5'-TGG GATTTGGTAACCCTTCA-3' and reverse, 5'-CCTTGAGCG AATAGCCTGAG-3'; c-Cbl forward, 5'-CCATGGCTCTGA AATCCACT-3' and reverse 5'-GGAGAATGTTCCCATCAG CA-3'; GAPDH forward, 5'-TGGGGAAGGTGAAGGTCGG AGTC-3' and reverse 5'-TCCCGTTCTCAGCCTTGACGG-3'.
Protein stability assay. Cells were cultured in the media containing various concentrations of SAHA for 24 h and then treated with 10 µg/ml of cycloheximide to block protein synthesis. Cellular proteins were harvested at different times after cycloheximide addition, and the Tie2 protein level was detected by western blotting. Tie2 protein level in the cells collected at time zero was defined as 100%.
Western blotting. Cells were treated with different concentrations of SAHA for 24 h. After treatment, cells were washed with cold PBS and lysed by RIPA buffer (50 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM EDTA, 0.5 M sucrose, 0.25% sodium deoxycholate, 10% glycerol, 1% NP-40 and protease inhibitors) on ice for 10 min. Cell debris was removed by centrifugation at 13,000 rpm at 4˚C for 10 min. Cell lysates were subjected to SDS-PAGE separation and subsequently transferred onto a polyvinylidene difluoride membrane (Millipore). The membranes were incubated with 5% non-fat milk in Tris-buffered saline and were probed with various primary antibodies. After extensive washing, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies and developed by enhanced chemiluminescence (ECL; Millipore) reagent according to the manufacturer's instructions.
Cell proliferation and flow cytometry. For cell proliferation assay, cells were seeded at a density of 7,500 cells/well in 96-well plates. After overnight incubation, cells were treated with different concentrations of SAHA for 48 h. MTT assay was carried out according to the manufacturer's instructions to investigate cellular growth. For flow cytometric analysis, cells were cultured in the medium containing various concentrations of SAHA for 48 h, washed with cold PBS and fixed in 70% ethanol overnight. Subsequently, cells were washed with cold PBS and stained with PI solution containing 20 µg/ml propidium iodide, 200 µg/ml RNase A and 0.1% Triton X-100 for 30 min. Cell cycle analysis was performed by using Epics XL-MCL flow cytometry (Beckman Coulter, Miami, FL, USA).
Tube formation and sprouting assay. Tube formation and sprouting assays were performed as previously described (25) . Statistical analysis. All data are expressed as the means ± SE. The Student's t-test was used to evaluate the differences between various experimental groups. P-value <0.05 was considered to indicate a statistically significant result.
Results
SAHA inhibits the proliferation of LEC-like FP01 cells.
Culture of primary LECs is difficult as only a limited cell number can be isolated by using specific markers such as LYVE-1. To study LEC function, we recently established an LEC-like cell line (FP01) by overexpressing the master LEC transcription factor PROX1 in EA.hy926 endothelial cells (25) . FP01 cells exhibited a gene expression pattern similar to primary LECs. In addition, these cells expressed vascular endothelial growth factor receptor 3 (VEGFR3) and their proliferation, sprouting and tube formation were strongly stimulated by VEGF-C (25). Our results suggest that the FP01 cell line is a useful model for functional investigation of LECs. As shown in Fig. 1A , SAHA dose-dependently inhibited the proliferation of FP01 cells and this drug at 10 µM suppressed cell growth by 60-70%. Flow cytometric analysis demonstrated that SAHA increased the percentage of cells at the G0/G1 and G2/M phases (Fig. 1B) . Conversely, the percentage of cells at S phase was significantly reduced. Expression of CDKIs (p21 and p27) was not changed by SAHA (Fig. 1C) . Interestingly, cyclin D1 and B1 were increased while cyclin E was reduced. Since constitutive expression of cyclin D1 and B1 will prevent G1/S progression and mitotic exit, our data suggest that SAHA-induced G0/G1 and G2/M cell accumulation may be associated with upregulation of cyclin D1 and B1. In addition, reduction in cyclin E reflected the decrease of cells at S phase.
SAHA inhibits sprouting and tube formation of FP01 cells.
For induction of lymphangiogenesis, LECs need to spout from existing lymphatic vessels and then organize into a new tube network structure. Treatment of SAHA repressed the sprouting of FP01 cells in the 3D culture ( Fig. 2A) . In addition, organization of the tube network structure of FP01 cells on matrix-coated plates was also significantly inhibited (Fig. 2B) . Our data demonstrated that SAHA at the concentration of 2.5 µM inhibited the number of vessel joints by 70-80% (Fig. 2B) .
SAHA inhibits Tie2 transcription. The Ang/Tie signaling pathway is important for LEC maturation and biological function. As shown in Fig. 3A , FP01 cells expressed Ang1, Ang2, Tie1 and Tie2. Interestingly, we found that SAHA repressed Tie2 expression in a dose-dependent manner while Tie1 and Ang2 were not affected and Ang1 was only marginally reduced. We also used primary cultured LECs to confirm our results. Consistent with the data of FP01 cells, only Tie2 expression was significantly inhibited by SAHA (Fig. 3B) . Western blot analysis demonstrated that the Tie2 protein level was dramatically reduced by SAHA in FP01 cells (Fig. 3C) . Since Tie2 mRNA was attenuated, a direct inhibition of Tie2 transcription by SAHA was investigated. We cloned the proximal promoter region of the human Tie2 gene and generated a series of deletion mutants of the promoter-luciferase reporter (Fig. 4A) . The reporter containing the -703/+232 region of the human Tie2 gene exhibited high luciferase activity in FP01 cells indicating that this region is the major regulatory region of Tie2 expression in endothelial cells (Fig. 4B) . These data were consistent with our RT-PCR data showing a high level of Tie2 mRNA in FP01 cells. Deletion mutant containing the -357/+232 region was also repressed by SAHA. Conversely, luciferase activity of the deletion mutant containing the -138/+232 region was very low and was not affected by SAHA suggesting that the -357/-138 promoter region is important for Tie2 transcription in FP01 cells and is responsible for the inhibition by SAHA (Fig. 4D) . Bioinformatics prediction revealed several transcription factor binding sites including Sp1, Sp3, NF-κB and Ets-1 in this region. However, ectopic expression of Sp1 or Ets-1 could not rescue downregulation of Tie2 by SAHA (Fig. 4C) . These data indicate that SAHA inhibits Tie2 transcription via the -357/-138 promoter region and this effect is independent of Sp1 and Ets-1.
Induction of Tie2 protein degradation via the ubiquitin/
proteasome pathway by SAHA. Although SAHA directly inhibits Tie2 gene transcription, our data demonstrated that the reduction in Tie2 protein was more significant than that of Tie2 mRNA. In addition, SAHA at the concentration of 1.25 µM did not affect the Tie2 mRNA level while it dramatically reduced Tie2 protein level (Fig. 3A and C) . These results suggest a transcription-independent inhibitory effect of SAHA on Tie2 expression. We blocked protein synthesis by cycloheximide and examined Tie2 protein stability in control and SAHA-treated cells. Our results showed that SAHA reduced Tie2 protein by 40% at 13 h after exposure to cycloheximide (Fig. 5A and B) . Conversely, no significant reduction in Tie2 protein was found in the control group suggesting that SAHA increased Tie2 degradation. Treatment of MG132 (proteasome inhibitor) but not chloroquine (autophagy inhibitor) or leupeptin (protease inhibitor) rescued SAHA-induced downregulation of Tie2 protein. These data suggest the involvement of the ubiquitin/proteasome pathway in Tie2 degradation (Fig. 5C) . A previous study demonstrated that the E3 ligase responsible for the ubiquitination of Tie2 protein is c-Cbl (26) . We found that SAHA increased the mRNA level of c-Cbl in a dose-dependent manner (Fig. 6A) . The induction was rapidly detected at 6 h after SAHA treatment and high expression of c-Cbl was persistently found at 24 h (Fig. 6A) . c-Cbl protein was also upregulated dose-dependently in FP01 cells (Fig. 6B) . More importantly, knockdown of c-Cbl increased the basal Tie2 protein level and effectively reversed SAHA-induced downregulation of Tie2 (Fig. 6C) . Collectively, we demonstrated that SAHA upregulated c-Cbl expression and induced Tie protein degradation via the ubiquitin/proteasome pathway.
Discussion
Solid tumors including breast, lung, gastric, head and neck and prostate carcinomas are dependent on angiogenesis and lymphangiogenesis to promote tumor growth and to increase cancer metastasis. In the present study, we provide evidence that the clinically used HDAC inhibitor SAHA suppresses proliferation, sprouting and tube formation of LECs. The anti-angiogenic activity of SAHA was firstly demonstrated by Deroanne et al (27) . By using human umbilical cord endothelial cells (HUVEC) as a model, they showed that Trichostatin-A (TSA) and SAHA prevented VEGF-stimulated HUVECs from invading a type I collagen gel and forming capillary-like structures. In addition, they also found that TSA inhibited the expression of VEGFR1, VEGFR2 and neuropilin-1 induced by VEGF. The in vivo effect of SAHA on angiogenesis was shown by Ugur et al (28) . The authors demonstrated that SAHA repressed tumor growth of glioma in an orthotopic animal model. They found that a 30% reduction in the angiogenesis rate was detected in SAHA-treated animals.
Subsequently, Mühlethaler-Mottet et al (29) also showed that SAHA and TSA strongly impaired hypoxia-induced VEGF expression and secretion in neuroblastoma cells. In addition to the inhibition of pro-angiogenic factors, HDAC inhibitors also stimulated the expression of anti-angiogenic factors to attenuate tumor angiogenesis. For example, a disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1), an anti-angiogenic proteinase, was upregulated by HDAC inhibitors in lung cancer cells (30) . These results support the anti-angiogenic activity of HDAC inhibitors. However, whether HDAC inhibitors can inhibit lymphangiogenesis is unclear. Induction of tumor lymphangiogenesis consists of two main steps. First, cancer cells secrete pro-lymphangiogenic factors including VEGF-A, VEGF-C and fibroblast growth factor-2 to stimulate the proliferation of quiescent LECs. Second, the stimulated LECs sprout from the lymphatic vessels, migrate toward tumors and form a new tube structure. Thus, both cancer cells and LECs are important for lymphangiogenesis. We recently demonstrated that SAHA attenuated the expression and production of VEGF-C in breast cancer cells (31) . We now demonstrate that SAHA also suppresses the proliferation, sprouting and tube formation of LECs. Our results suggest that SAHA is a potent anti-lymphangiogenic drug by inhibiting both cancer cells and LECs.
Another important finding of this study is the identification of Tie2 as a molecular target of SAHA. The Ang/Tie signaling pathway is known to play a crucial role in angiogenesis and lymphangiogenesis. Therefore, several strategies have been developed to inhibit this signaling pathway. The first strategy is targeting the Tie2 receptor. To date, a number of Tie2 kinase inhibitors have been tested in cell-based assays or in animal studies (32) . However, only a few compounds have advanced to clinical trials. For example, CEP-11981 is now undergoing Phase I study in patients with advanced solid tumors. However, this drug inhibits Tie2, VEGFRs and FGFRs. Thus, it is not truly Tie2 selective. The second strategy is Ang1 or Ang2 traps. For example, AMG-386 is a peptibody developed to target both Ang1 and Ang2 (33) . Peptibodies, an alternative therapeutic format to monoclonal antibodies, consist of biologically active peptides grafted onto an Fc domain. This design has benefits to increase selectivity by the active peptide domain and to retain the desirable features of antibodies to prolong plasma residency time (34, 35) . AMG-386 is now undergoing Phase I and II trials, either alone or in combination with chemotherapeutic drugs, for the treatment of various cancers (36) . In the present study, we explored SAHA as a new Tie2 inhibitor by downregulating its expression in LECs. In addition, we elucidated the underlying mechanisms and found that SAHA suppressed Tie2 via repression of gene transcription and promotion of protein degradation via the ubiquitination/proteasome pathway.
